Condition: Hemophilia A · Hemophilia B · Factor VII Deficiency · Sponsor: Shanghai RAAS Blood Products Co., Ltd.
The purpose of this study is to evaluate the safety, tolerability, immunogenicity , PK, and PD of a single dose of SR604 in participants with Hemophilia A or Hemophilia B, with or without inhibitors （Part A）and to evaluate the safety, PK, PD, and efficacy of multiple doses of SR604 in participants with Hemophilia A or Hemophilia B, or Factor VII (FVII) deficiency, with or without inhibitors (Part B and Part C).
This description comes directly from the study's public registry record.
Research and Development · 862122130888 · hanyu@raas-corp.com
Always discuss trial participation with your own doctor first.
| Xiangya Hospital of Central South University | Changsha, China | Recruiting |
| The First Affiliated Hospital of University of Science and Technology of China | Hefei, China | Recruiting |
| Jinan Central Hospital | Jinan, China | Recruiting |
| The First Hospital of Lanzhou University | Lanzhou, China | Recruiting |
| Ruijin Hospital Shanghai Jiaotong University School of Medicine | Shanghai, China | Completed |
| The Second Hospital of Shanxi Medical University | Taiyuan, China | Recruiting |
| Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences | Tianjin, China | Completed |
| Xian Central Hospital | Xi'an, China | Recruiting |
| Zhengzhou People's Hospital | Zhengzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07644832